Study S000999

An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02072096
Acronym: IMPERIUM
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: TERMINATED
Enrollment: 192
Start: 2014-02
Primary completion: 2015-10
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Glimepiride; DRUG:Metformin; DRUG:Pioglitazone; DRUG:Acarbose; DRUG:Linagliptin; DRUG:Sitagliptin; DRUG:Liraglutide; DRUG:Insulin Glargine; DRUG:Exenatide once weekly (QW); DRUG:Exenatide twice daily (BID)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:F3Z-MC-IOQL; EUDRACT_NUMBER:2013-001473-24

Registered primary outcomes

Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia [Baseline to last participant visit (up to 72 weeks)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016554	Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM). Heller SR, Diabetes, obesity & metabolism	2018	Randomized trial	PMID 28671753 DOI	cites ClinicalTrials.gov:NCT02072096; registry reference DERIVED:28671753